|
|
Article: Unigene, Glaxo Licensing Deal: Potential $150M For Bone Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Although still trading at under a dollar, Unigene Laboratories Inc. saw its stock jump 63 percent on news that GlaxoSmithKline plc signed a licensing deal worth up to $150 million for an oral parathyroid hormone (PTH) analogue still in preclinical studies for osteoporosis.
oThatEs unusual for them,o said Ronald Levy, executive vice president of Fairfield, N.J.-based Unigene. oThey wouldnEt come in this early unless they saw this as a sterling opportunity.o Glaxo, he added, owants to begin the tech transfer today, but we might have to wait a little bit longer.o
UnigeneEs stock (OTCBB:UGNE) closed Monday at 88 cents, up 34 ...